Forest acquisition whets M&A appetite

Share this article:

Actavis's Forest acquisition has piqued industry interest in Teva Pharmaceutical. Bloomberg reports that the Maxim Group thinks that the Actavis move has boosted “prospects that Teva could be acquired next.” Among Maxim's reasons: a new CEO, a shrinking executive board, and a cost-cutting strategy.

Teva would not comment on Bloomberg's story.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.